Lacrat (Ticagrelor)

Ticagrelor reversibly blocks the platelet P2Y12 ADP receptor, preventing ADP‑mediated activation of the GPIIb/IIIa complex. This inhibition stops platelets from aggregating, thereby reducing the formation of arterial clots that can lead to heart attacks or strokes.

The dosage of Lacrat is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and concomitant therapies. The prescriber will select the appropriate strength and dosing schedule according to approved guidelines.

Safety data for ticagrelor in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Lacrat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to ticagrelor is clopidogrel, another P2Y12 inhibitor. Ticagrelor provides more rapid and consistent platelet inhibition without needing metabolic activation, which can result in a quicker onset of action and potentially greater efficacy in acute coronary settings.

Lacrat tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lacrat is taken orally as a tablet. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider. It is usually taken with or without food, as directed.

The most serious risks include severe or uncontrolled bleeding, hypersensitivity reactions such as rash or anaphylaxis, and rare hepatic injury. Patients should seek immediate medical attention if they experience signs of major bleeding, severe rash, or jaundice.

Lacrat is contraindicated in patients with active pathological bleeding, a history of intracranial hemorrhage, severe hepatic impairment, or known hypersensitivity to ticagrelor or any of the tablet’s excipients. Clinicians should assess each patient’s medical history before initiating therapy.